Skip to main content
Tagasi

EVS-EN ISO 10993-1:2026

Meditsiiniseadmete bioloogiline hindamine. Osa 1: Bioohutuse hindamise nõuded ja üldprintsiibid riskihaldusprotsessis

Üldinfo

Kehtiv alates 15.01.2026
Alusdokumendid
ISO 10993-1:2025; EN ISO 10993-1:2025
Direktiivid või määrused
puuduvad

Standardi ajalugu

Staatus
Kuupäev
Tüüp
Nimetus
15.01.2026
Põhitekst
31.12.2020
Põhitekst

ISO 10993-1 specifies the requirements and general principles governing the biological evaluation of medical devices within a risk management process according to ISO 14971.

This standard applies to the biological evaluation of medical devices that have direct contact or indirect contact with either:

—  a patient's body during intended use or reasonably foreseeable misuse or
—  the body of other users who are not patients, if the medical device is intended for personal protection (e.g. medical gloves, surgical masks).

Biological evaluation assesses the biological safety of the medical device by considering the biological risks associated with:

— constituents of a medical device and
— tissue-device interactions (including physical effects).

The biological evaluation specified in ISO 10993-1 can address the biological safety of the medical device, considering the life cycle from design and development through initial use of the finished medical device to final decommissioning or withdrawal from use. The biological evaluation considers both the biological safety of the finished device in first use, and the significance of any changes to the medical device which can occur throughout the life cycle.

However, the evaluation of risks related to environmental impacts of decommissioning of medical devices are not within the scope of ISO 10993-1. This document does not mandate re-testing of medical devices that are already on the market and have established and acceptable safety profiles (see 6.6.2).

ISO 10993-1 can be useful to support clinical or usability evaluations of medical devices. For example, a biological evaluation is a pre-requisite for conducting a clinical trial. This means that principles outlined in this document can be applied to the evaluation of prototype or development stage devices, as well as to finished medical devices.

Other parts of the ISO 10993 series cover specific aspects of biological evaluation, such as chemical characterisation, biological testing, sample preparation, animal welfare and toxicological risk assessment. For some types of medical devices, specific requirements from other standards (outside the ISO 10993 series) can be considered with a justification for the approach taken if there are differences between the requirements of the ISO 10993 series and those provided in other standards.

The evaluation of risks related to infectious agents [e.g. bacteria, moulds, yeasts, viruses, transmissible spongiform encephalopathy (TSE) agents] is not within the scope of ISO 10993-1.

ISO 10993-1:2025 text has been approved in Europe as EN ISO 10993-1:2025 without any changes.

Nõutud väljad on tähistatud *

*
*
*
PDF
32,24 € koos KM-ga
Paber
32,24 € koos KM-ga
Sirvi standardit alates 2,48 € koos KM-ga
Standardi monitooring

Teised on ostnud veel

Põhitekst + muudatus

EVS-EN ISO 15223-1:2021+A1:2025

Meditsiiniseadmed. Tootjainfos kasutatavad tingmärgid. Osa 1: Üldnõuded
Uusim versioon Kehtiv alates 01.12.2025
Põhitekst + muudatus

EVS-EN ISO 10993-17:2023+A1:2025

Meditsiiniseadmete bioloogiline hindamine. Osa 17: Meditsiiniseadme osade toksikoloogilise riski hindamine
Uusim versioon Kehtiv alates 15.01.2026
Põhitekst + muudatus

EVS-EN ISO 10993-5:2009+A11:2025

Meditsiinivahendite bioloogiline hindamine. Osa 5: Katsed tsütotoksilisuse hindamiseks - in vitro meetodid
Uusim versioon Kehtiv alates 02.06.2025
Muudatus

EVS-EN ISO 15223-1:2021/A1:2025

Meditsiiniseadmed. Tootjainfos kasutatavad tingmärgid. Osa 1: Üldnõuded. Muudatus 1: Volitatud esindaja määratletud termini lisandus ja "EC-REP" muudetud tingmärk, mis poleks riigi- ega piirkonnapõhine
Kehtiv alates 01.12.2025